Morgan Stanley’s Pacer BioThreat Strategy ETF VIRS Stock Holding History

Morgan Stanley’s Portfolio VIRS Stock Details VIRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$48	–	8058
2024 Q2	$48	Buy	+1	New	+$36	﹤0.01%	7512

Other funds holding VIRS

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's VIRS Position: Q3 2024 in Review

Morgan Stanley sold out of Pacer BioThreat Strategy ETF (VIRS) in Q3 2024, closing a stake of 1 share — an estimated $48 sold.

Morgan Stanley first reported a position in VIRS in Q2 2024 and held it in 1 quarter. The position peaked at $48 in Q2 2024. 4 funds tracked by Wall St. Rank hold VIRS as of Q3 2024.

Morgan Stanley reported no remaining Pacer BioThreat Strategy ETF position as of Q3 2024 after selling out during the quarter.
Morgan Stanley sold 1 Pacer BioThreat Strategy ETF share in Q3 2024, an estimated $48.
Morgan Stanley first reported a position in Pacer BioThreat Strategy ETF in Q2 2024 and held it in 1 quarter.
Morgan Stanley's Pacer BioThreat Strategy ETF position peaked at $48 in Q2 2024.
4 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.